Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection

Journal of Virology

Volumn 88, Issue 22, 2014, Pages 13310-13321

  Cohen, Kristen ^a,b   Altfeld, Marcus ^c,d   Alter, Galit ^c   Stamatatos, Leonidas ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; CHEMOKINE RECEPTOR CXCR5; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; CXCR5 PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PDCD1 PROTEIN, HUMAN;

AICDA GENE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRUS LOAD; BLOOD; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONGITUDINAL STUDY; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; COHORT STUDIES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, CXCR5; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84908377312     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02186-14     Document Type: Article

References (68)

1. Binley J, Lybarger E, Crooks E, Seaman M, Gray E, Davis K, Decker J, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras G, Bibollet-Ruche F, Robinson J, Morris L, Shaw G, Montefiori D, Mascola J. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82: 11651-11668. http://dx.doi.org/10.1128/JVI.01762-08.
2. Doria-Rose N, Klein R, Daniels M, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles S, Wyatt R, Korber B, Mascola J, Connors M. 2010. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636. http://dx.doi.org/10.1128/JVI.01482-09.
3. Nandi A, Lavine C, Wang P, Lipchina I, Goepfert P, Shaw G, Tomaras G, Montefiori D, Haynes B, Easterbrook P, Robinson J, Sodroski J, Yang X. 2010. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396: 339-348. http://dx.doi.org/10.1016/j.virol.2009.10.044.
4. Sather D, Armann J, Ching L, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769. http://dx.doi.org/10.1128/JVI.02036-08.
5. Simek M, Rida W, Priddy F, Pung P, Carrow E, Laufer D, Lehrman J, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee D, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker L, Pitisuttithum P, Paris R, Walker L, Poignard P, Wrin T, Fast P, Burton D, Koff W. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348. http://dx.doi.org/10.1128/JVI.00110-09.
6. van Gils M, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. 2009. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23:2405-2414. http://dx.doi.org/10.1097/QAD.0b013e32833243e7.
7. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251. http://dx.doi.org/10.1371/journal.ppat.1001251.
8. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206. http://dx.doi.org/10.1038/72309.
9. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U. S. A. 108:11181-11186. http://dx.doi.org/10.1073/pnas.1103012108.
10. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433. http://dx.doi.org/10.1371/journal.ppat.1000433.
11. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membraneproximal external region protect against mucosal challenge by simianhuman immunodeficiency virus SHIVBa-L. J. Virol. 84:1302-1313. http://dx.doi.org/10.1128/JVI.01272-09.
12. Marx PA, Compans RW, Gettie A, Staas JK, Gilley RM, Mulligan MJ, Yamshcikov GV, Chen D, Eldridge JH. 1993. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260:1323-1327. http://dx.doi.org/10.1126/science.8493576.
13. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
14. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U. S. A. 109:18921-18925. http://dx.doi.org/10.1073/pnas.1214785109.
15. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75: 8340-8347. http://dx.doi.org/10.1128/JVI.75.17.8340-8347.2001.
16. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys. Nature 503:224-228. http://dx.doi.org/10.1038/nature12744.
17. Sadjadpour R, Donau OK, Shingai M, Buckler-White A, Kao S, Strebel K, Nishimura Y, Martin MA. 2013. Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 87:8798-8804. http://dx.doi.org/10.1128/JVI.00878-13.
18. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Jr, Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA. 2013. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277-280. http://dx.doi.org/10.1038/nature12746.
19. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:118-122. http://dx.doi.org/10.1038/nature11604.
20. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622. http://dx.doi.org/10.1038/nm1244.
21. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederost B, Weber R, Stiegler G, Katinger H, Gunthard HF, Trkola A. 2007. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol. 81:8793-8808. http://dx.doi.org/10.1128/JVI.00598-07.
22. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12:396-407. http://dx.doi.org/10.1016/j.chom.2012.09.008.
23. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444. http://dx.doi.org/10.1146/annurev-immunol-030409-101256.
24. Basavapathruni A, Yeh WW, Coffey RT, Whitney JB, Hraber PT, Giri A, Korber BT, Rao SS, Nabel GJ, Mascola JR, Seaman MS, Letvin NL. 2010. Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys. J. Virol. 84:953-963. http://dx.doi.org/10.1128/JVI.01679-09.
25. Stamatatos L. 2012. HIV vaccine design: the neutralizing antibody conundrum. Curr. Opin. Immunol. 24:316-323. http://dx.doi.org/10.1016/j.coi.2012.04.006.
26. Haynes BF, Montefiori DC. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5:579-595. http://dx.doi.org/10.1586/14760584.5.4.579.
27. Eisen HN, Siskind GW. 1964. Variations in affinities of antibodies during the immune response. Biochemistry 3:996-1008. http://dx.doi.org/10.1021/bi00895a027.
28. French DL, Laskov R, Scharff MD. 1989. The role of somatic hypermutation in the generation of antibody diversity. Science 244:1152-1157. http://dx.doi.org/10.1126/science.2658060.
29. Siskind GW, Benacerraf B. 1969. Cell selection by antigen in the immune response. Adv. Immunol. 10:1-50. http://dx.doi.org/10.1016/S0065-2776(08)60414-9.
30. Weiss U, Zoebelein R, Rajewsky K. 1992. Accumulation of somatic mutants in the B cell compartment after primary immunization with a T cell-dependent antigen. Eur. J. Immunol. 22:511-517. http://dx.doi.org/10.1002/eji.1830220233.
31. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, NISC Comparative Sequencing Program, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496:469-476. http://dx.doi.org/10.1038/nature12053.
32. Crotty S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29:621-663. http://dx.doi.org/10.1146/annurev-immunol-031210-101400.
33. Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL, Srivastava M, Linterman M, Zheng L, Simpson N, Ellyard JI, Parish IA, Ma CS, Li QJ, Parish CR, Mackay CR, Vinuesa CG. 2009. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 31: 457-468. http://dx.doi.org/10.1016/j.immuni.2009.07.002.
34. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Forster R. 2000. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192:1545-1552. http://dx.doi.org/10.1084/jem.192.11.1545.
35. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. 2000. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192:1553-1562. http://dx.doi.org/10.1084/jem.192.11.1553.
36. Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, Wang YH, Dong C. 2009. Bcl6 mediates the development of T follicular helper cells. Science 325:1001-1005. http://dx.doi.org/10.1126/science.1176676.
37. + T cells. J. Exp. Med. 193: 1373-1381. http://dx.doi.org/10.1084/jem.193.12.1373.
38. +) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34:108-121. http://dx.doi.org/10.1016/j.immuni.2010.12.012.
39. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, Sallusto F, Tangye SG, Mackay CR. 2011. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J. Immunol. 186:5556-5568. http://dx.doi.org/10.4049/jimmunol.1002828.
40. MacLeod MK, David A, McKee AS, Crawford F, Kappler JW, Marrack P. 2011. Memory CD4 T cells that express CXCR5 provide accelerated help to B cells. J. Immunol. 186:2889-2896. http://dx.doi.org/10.4049/jimmunol.1002955.
41. Hale JS, Youngblood B, Latner DR, Mohammed AU, Ye L, Akondy RS, Wu T, Iyer SS, Ahmed R. 2013. Distinct memory CD4 T cells with commitment to T follicular helper-and T helper 1-cell lineages are generated after acute viral infection. Immunity 38:805-817. http://dx.doi.org/10.1016/j.immuni.2013.02.020.
42. Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, Su LF, Cubas R, Davis MM, Sette A, Haddad EK, International AIDS Vaccine Initiative Protocol C Principal Investigators, Poignard P, Crotty S. 2013. Human circulating PD-1CXCR3CXCR5 memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39:758-769. http://dx.doi.org/10.1016/j.immuni.2013.08.031.
43. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, Manku H, Vyse TJ, Roncador G, Huttley GA, Goodnow CC, Vinuesa CG, Cook MC. 2010. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62:234-244. http://dx.doi.org/10.1002/art.25032.
44. Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, Ambrozak DR, Sandler NG, Timmer KJ, Sun X, Pan L, Poholek A, Rao SS, Brenchley JM, Alam SM, Tomaras GD, Roederer M, Douek DC, Seder RA, Germain RN, Haddad EK, Koup RA. 2012. CD4 T follicular helper cell dynamics during SIV infection. J. Clin. Investig. 122:3281-3294. http://dx.doi.org/10.1172/JCI63039.
45. Xu Y, Weatherall C, Bailey M, Alcantara S, De Rose R, Estaquier J, Wilson K, Suzuki K, Corbeil J, Cooper DA, Kent SJ, Kelleher AD, Zaunders J. 2013. Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J. Virol. 87:3760-3773. http://dx.doi.org/10.1128/JVI.02497-12.
46. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, De Leval L, Graziosi C, Pantaleo G. 2013. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210:143-156. http://dx.doi.org/10.1084/jem.20121932.
47. Cubas RA, Mudd JC, Savoye AL, Perreau M, van Grevenynghe J, Metcalf T, Connick E, Meditz A, Freeman GJ, Abesada-Terk G, Jr, Jacobson JM, Brooks AD, Crotty S, Estes JD, Pantaleo G, Lederman MM, Haddad EK. 2013. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 19:494-499. http://dx.doi.org/10.1038/nm.3109.
48. Boswell KL, Paris R, Boritz E, Ambrozak D, Yamamoto T, Darko S, Wloka K, Wheatley A, Narpala S, McDermott A, Roederer M, Haubrich R, Connors M, Ake J, Douek DC, Kim J, Petrovas C, Koup RA. 2014. Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. PLoS Pathog. 10:e1003853. http://dx.doi.org/10.1371/journal.ppat.1003853.
49. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100:9440-9445. http://dx.doi.org/10.1073/pnas.1530509100.
50. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, Flanders MD, Cutler S, Yudanin N, Muller MI, Davis I, Farber D, Hartjen P, Haag F, Alter G, Schulze zur Wiesch J, Streeck H. 2012. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Investig. 122:3271-3280. http://dx.doi.org/10.1172/JCI64314.
51. Simmons RP, Scully EP, Groden EE, Arnold KB, Chang JJ, Lane K, Lifson J, Rosenberg E, Lauffenburger DA, Altfeld M. 2013. HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. AIDS 27:2505-2517. http://dx.doi.org/10.1097/01.aids.0000432455.06476.bc.
52. Widney DP, Breen EC, Boscardin WJ, Kitchen SG, Alcantar JM, Smith JB, Zack JA, Detels R, Martinez-Maza O. 2005. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J. Interferon Cytokine Res. 25:702-706. http://dx.doi.org/10.1089/jir.2005.25.702.
53. Cagigi A, Mowafi F, Phuong Dang LV, Tenner-Racz K, Atlas A, Grutzmeier S, Racz P, Chiodi F, Nilsson A. 2008. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood 112:4401-4410. http://dx.doi.org/10.1182/blood-2008-02-140426.
54. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83:188-199. http://dx.doi.org/10.1128/JVI.01583-08.
55. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W, van der Burg M, van Dongen JJ, Orlowska-Volk M, Knoth R, Durandy A, Draeger R, Schlesier M, Peter HH, Grimbacher B. 2006. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 107: 3045-3052. http://dx.doi.org/10.1182/blood-2005-07-2955.
56. +CD4 germinal center Th cells. J. Immunol. 177:4927-4932. http://dx.doi.org/10.4049/jimmunol.177.7.4927.
57. + follicular helper T cells accumulate in resting human lymph nodes and have superior B cell helper activity. Int. Immunol. 26:183-192. http://dx.doi.org/10.1093/intimm/dxt058.
58. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
59. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, Chan TD, Palendira U, Bustamante J, Boisson-Dupuis S, Choo S, Bleasel KE, Peake J, King C, French MA, Engelhard D, Al-Hajjar S, Al-Muhsen S, Magdorf K, Roesler J, Arkwright PD, Hissaria P, Riminton DS, Wong M, Brink R, Fulcher DA, Casanova J-L, Cook MC, Tangye SG. 2010. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207: 155-171. http://dx.doi.org/10.1084/jem.20091706.
60. Lafarge S, Hamzeh-Cognasse H, Richard Y, Pozzetto B, Cogne M, Cognasse F, Garraud O. 2011. Complexes between nuclear factorkappaB p65 and signal transducer and activator of transcription 3 are key actors in inducing activation-induced cytidine deaminase expression and immunoglobulin A production in CD40L plus interleukin-10-treated human blood B cells. Clin. Exp. Immunol. 166:171-183. http://dx.doi.org/10.1111/j.1365-2249.2011.04465.x.
61. +) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J. Exp. Med. 193:297-305. http://dx.doi.org/10.1084/jem.193.3.297.
62. Schwickert TA, Victora GD, Fooksman DR, Kamphorst AO, Mugnier MR, Gitlin AD, Dustin ML, Nussenzweig MC. 2011. A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J. Exp. Med. 208:1243-1252. http://dx.doi.org/10.1084/jem.20102477.
63. Victora GD, Schwickert TA, Fooksman DR, Kamphorst AO, Meyer-Hermann M, Dustin ML, Nussenzweig MC. 2010. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143:592-605. http://dx.doi.org/10.1016/j.cell.2010.10.032.
64. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR, NISC Comparative Sequencing Program. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602. http://dx.doi.org/10.1126/science.1207532.
65. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637. http://dx.doi.org/10.1126/science.1207227.
66. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. 2013. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153:126-138. http://dx.doi.org/10.1016/j.cell.2013.03.018.
67. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
68. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, NISC Comparative Sequencing Program, Becker J, Benjamin B, Blakesley R, Bouffard G, Brooks S, Coleman H, Dekhtyar M, Gregory M, Guan X, Gupta J, Han J, Hargrove A, Ho SL, Johnson T, Legaspi R, Lovett S, Maduro Q, Masiello C, Maskeri B, McDowell J, Montemayor C, Mullikin J, Park M, Riebow N, Schandler K, Schmidt B, Sison C, Stantripop M, Thomas J, Thomas P, Vemulapalli M, Young A, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-476. http://dx.doi.org/10.1038/nature12053.